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Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis.
Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated.
Results: The median age at ruxolitinib initiation was 62 (28–87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms
were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10–40). Dose change was made in 69 (39.2%) patients.
Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean
spleen sizes before and after ruxolitinib treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95 mm, respectively (p < 0.001). There
was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median
follow up was 10 (1–55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73).
Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration
can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment.
Key words: Myelofibrosis, treatment, survival, ruxolitinib, adverse events

1. Introduction
Myelofibrosis (MF) is a chronic myeloproliferative
neoplasm that is characterized by extensive fibrosis of the
bone marrow, splenomegaly, and constitutional symptoms
such as night sweating, weight loss, and fever [1,2]. MF
can present as a primary (PMF) or secondary disease after

essential thrombocythemia (ET) or polycythemia vera
(PV) [2,3]. Prognosis is assessed by the several prognostic
scoring systems such as the International Prognostic
Scoring System (IPSS), dynamic-IPSS (DIPSS), and
DIPSS-plus [1]. Life expectancy ranges between 2–11
years according to IPSS [1].
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Janus kinase 2 (JAK2) is a member of intracellular,
nonreceptor tyrosine kinases (JAK family) that transduce
cytokine mediated signals via the JAK-signal transducer
and activator of transcription (STAT) pathway [4,5]. About
65% of MF patients carry a gain of function mutation in
JAK2 gene (JAK2 V617F) [1]. Mutations in the calreticulin
and The myeloproliferative leukemia virus oncogene
(MPL) gene, which also lead to dysregulated JAK/STAT
signaling, is identified in patients who do not have the
JAK2 mutation [1]. Ruxolitinib is an oral JAK1/JAK2
inhibitor that has demonstrated significant improvement
in splenomegaly and constitutional symptoms, and
an increase in overall survival (OS) in COMFORT-I
and COMFORT-II studies in patients with MF [6–10].
Therefore, ruxolitinib was approved by FDA for the
treatment of intermediate- and high-risk MF patients. The
JUMP trial which was constructed as phase 3b expanded
access trial, covers patients in countries without access to
ruxolitinib outside of a clinical study and it also includes
patients who classified as intermediate-1 risk. In this
study, 62% of patients achieved a > 50% of reduction from
baseline of palpable spleen length. The most common
adverse events were anemia, thrombocytopenia, primarily
grade 1/2 diarrhea, pyrexia, fatigue, asthenia, and
infections [11].
In the literature, there are some reports that evaluated
the efficacy and safety of ruxolitinib outside of clinical trials
in patients with MF. These studies reported reduction in
spleen size and improvement of constitutional symptoms
[12–14].
We designed this multicenter study to retrospectively
evaluate the efficacy and safety of ruxolitinib in Turkish
patients with MF in the real-life clinical practice.
2. Material and methods
2.1. Patients
This study was designed as a retrospective, multicenter
study from Turkey, and approved by Ege University Ethical
Committee with number of 16–6.1/9. Across all of Turkey,
15 centers were enrolled in the study. We reviewed the
medical records of 176 patients with MF from December
2012 to November 2017. The primary objective of the study
was the evaluation of the efficacy and safety of ruxolitinib
in patients with myelofibrosis in Turkey.
Patients’ ≥ 18 years of age who diagnosed PMF, post-PV
or post-ET MF were classified as intermediate- or high risk
disease stratified based on the DIPSS or DIPSS plus were
included in this study [15,16]. Diagnosis was confirmed
according to the 2008 World Health Organization
(WHO) criteria and post-PV or -ET MF was diagnosed in
accordance with the criteria of the International Working
Group of Myelofibrosis Research and Treatment [3,17].
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2.2. Treatment
In Turkey, ruxolitinib was firstly obtained from the official
compassionate use program approved by the Turkish
health authorities since October 2011. In June 2016, the
commercial use of ruxolitinib was approved and started,
and compassionate use program was ended. Patients were
only allowed to enter this program if they had a platelet
count of 100.000/mm3 or higher. All patients provided
written informed consent before the use of this drug. The
initial dosage was determined by the physicians according
to patient’s clinical condition and platelet count at baseline,
ranging from 5 to 20 mg twice daily. The dosage was
adjusted every 2–4 weeks based on the platelet counts and
the severity of nonhematological toxicities if existed.
A special case report form was used for data collection.
Patients’ age of diagnosis, sex, constitutional symptoms,
spleen size before and after ruxolitinib treatment, and
other clinical parameters were noted. We also collected
data of side effects, leukemic evolution, and death.
Response to treatment was reported by the primary
treating physicians and analyzed as categorical variables
(yes or no for constitutional symptom improvement
and spleen size reduction), and as a continuous variable
(decrease in spleen size). Spleen length was assessed with
abdominal ultrasonography or palpation on physical
examination.
2.3. Statistical analysis
All the statistical analyses were performed by using the
data obtained from the patients’ files. Demographic and
disease characteristics of the patients were summarized for
all patients using descriptive statistics.
Statistical analyses were performed using SPSS v.16.0
(SPSS Inc., Chicago, IL, USA). The variables were first
assessed by Kolmogorov–Smirnov testing in terms of
normal distribution. The results were provided as mean
± SD for normally distributed variables and as median
(min-max) for nonnormally distributed parameters.
Categorical and continuous variables were compared
with chi-square and Mann–Whitney U tests, respectively.
Logistic regression analysis was performed to correlate
spleen response and constitutional symptom response
with several baseline features, such as, age > 65 years,
sex, diagnostic subgroups, DIPSS score, leukocytosis (>
25.000/µL), hemoglobin < 10 g/dL, platelet < 200.000/µL,
blast cells > 1%, JAK2V617F mutation status, and time
between diagnosis to ruxolitinib treatment. All p-values
were two-tailed and statistical significance was set at the
level of p < 0.05.
Overall survival (OS) was defined from the date of
ruxolitinib start to the time of death or last follow-up.
OS evaluation was performed using the Kaplan–Meier
method.
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3. Results
3.1. Baseline characteristics
From 15 centers, 176 patients (94 male; 53.4%, 82 female,
46.6%) were enrolled the study. Patient demographic
information and baseline clinical characteristics were
shown in Table 1. The median age at diagnosis and
ruxolitinib initiation was 59 years (range: 19–83) and 62
years (range: 28–87), respectively. The median interval
between diagnosis and the initiation of ruxolitinib was
41.5 months (range: 0–342). One hundred of patients
(56.8%) were diagnosed with PMF, 47 (26.7%) and 29
(16.5%) of patients were post-PV MF and post-ET MF,
respectively. Hepatomegaly was detected in 89/171 of
the patients (52%) and constitutional symptoms were
observed in 149/176 (84.7%). Pruritus and minor

neurological symptoms were observed in 26.1% and 20.5%
of the patients, respectively. Thrombosis (8 arterial, 14
venous, and 2 had both arterial and venous thrombosis)
before diagnosis was detected in 13.1%, whereas bleeding
was a more rare complication before diagnosis affected
6.3% of the patients. Most common sites of bleeding
were epistaxis, gastrointestinal, and cerebral hemorrhage
reported in 5, 2, and 2 patients, respectively. Gingival and
urinary hemorrhage was observed in 2 patients. Only 2
patients (1.1%) had concomitant cancer history. These
were cholangiocellular cancer in one patient and gastric
cancer in the other patient. One-hundred and thirteen of
all patients (64.2%) were positive for the JAK2 mutation.
Eighty patients’ blood analyzed for the MPL mutation.
MPL mutation was detected in 6 (7.5%) of 80 patients.

Table 1. Patient demographics and baseline clinical characteristics.
Characteristics

n = 176

The median age of ruxolitinib treatment, years (range)

62 (28–87)

Sex, n (%)
Male

94 (53.4)

Female

82 (46.6)

Myelofibrosis subtypes, n (%)
PMF

100 (56.8)

Post-PV MF

47 (26.7)

Post-ET MF

29 (16.5)

DIPSS risk category, n (%)

137

Intermediate-1

44 (32.1)

Intermediate-2

80 (58.4)

High

13 (9.5)

DIPSS-plus risk category, n (%)

39

Intermediate-1

4 (10.3)

Intermediate-2

19 (48.7)

High

16 (41)

Hepatomegaly (yes/no/NA) (%)

89/82/5 (50.6/46.6/2.8)

Spleen size before ruxolitinib (mm) (mean ± SD )

219.67 ± 46.79

Constitutional symptoms (yes/no) (%)

149/27 (84.7/15.3)

White blood cell (´ 10 /µL) (range)

11 (0.8–68.9)

Platelet (´103/µL) (range)

348 (42–1920)

Hemoglobin (g/dL) (range)

10.7 (6.6–14.9)

Time between diagnosis to ruxolitinib, months, median (range)

41.5 (0–342)

JAK2 mutation (yes/no/NA) (%)

113/55/8 (64.2/31.3/4.5)

Karyotype (yes/no) (%)

31/145 (17.6/82.4)

Peripheral blood blast (%) (range)

0 (0–8)

RBC transfusion history (yes/no), n (%)

108/68 (61.4/38.6)

3
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Conventional cytogenetic analysis was applied in 31
patients. Twenty three patients had normal karyotypes and
8 had complex karyotypes.
Antiplatelet, androgen, and steroid treatments were
used in 94 (53.4%), 18 (10.2%), and 11 (6.3%) patients,
respectively. Seven patients (4%) had history of erythrocyte
stimulating agent treatment. Splenectomy and stem cell
transplantation was rarely used, in 7 (6%) and 1 patient,
respectively.
Cytoreductive treatment was used in 153 (86.9%)
patients. The most common drug as the first line
treatment was hydroxyurea (131 of 153 patients, 85.6%).
Twelve (7.8%) of 153 received anagrelide therapy, 8
(5.2%) interferon and 2 (1.3%) thalidomide. Second line
treatment was used in 41 (23.3%) patients. Anagrelide and
interferon were the most common second line treatment
agents (17 and 15 patients, respectively). Only 8 patients
(4.5%) had third line treatment. The most common agent
was interferon (n = 5).
3.2. Ruxolitinib treatment
The median initial dose of ruxolitinib was 30 mg per day
(range:10–40 mg).The initial ruxolitinib doses were 20 mg
BID, 15 mg BID, 10 mg BID and 5 mg BID in 67 (38.1%), 36
(20.5%), 46 (26.1%), and 27 (15.3%) patients, respectively.
Ruxolitinib dose modifications were necessary in 46% of
150 patients. Ruxolitinib treatment details were given in
Table 2. After dose modifications, the median ruxolitinib
doses achieved was still 30 mg per day (range: 10–40 mg).
The maximum ruxolitinib doses achieved were 20 mg BID,
15 mg BID, 10 mg BID and 5 mg BID in 52 (29.5%), 55
(31.3%), 62 (35.2%), and 7 (4%) patients, respectively.
3.3. Efficacy of treatment
Data of improvement in constitutional symptoms and
spleen response were available in 152 (86.3%) and
150 (85.2%) patients, respectively. Improvement in
constitutional symptoms was seen in 136/152 (89.4%)
patients. A reduction in splenomegaly was seen in 102/150
(68%) patients.
The mean spleen sizes before and after ruxolitinib
treatment were 219.67 ± 46.79 mm versus 199.49 ± 40.95,

respectively (p < 0.001). A ≥ 50% reduction from baseline
in palpable spleen length was seen in 17/39 (43.5%)
patients at any time during the study. Mean percentage
change from baseline to week 12 in ultrasonographic
spleen length showed in Figure 1. Mean percentage change
from baseline in palpable spleen length showed in Figure
2. Among baseline features that were tested for correlation
with subsequent spleen response and constitutional
symptom response, none were significantly associated
with these. The data showed in Table 3. There was no
correlation between maximum ruxolitinib doses achieved
and reduction in spleen size.
3.4. Safety and outcome
Adverse events data were available in 132 (75%) of all patients.
Forty seven (35.6%) of 132 patients had hematological and
20 (15.2%) had nonhematological adverse events. Adverse
events are illustrated in Table 4. Patients who had anemia
treated with red blood cell transfusions. For management
of thrombocytopenia, ruxolitinib dose reduction was
performed. Nonhematological adverse events (AST-ALT
elevation, abdominal pain, rash, nausea, gingival bleeding,
and electrolyte imbalance) were treated with supportive
care. Infections were treated with antimicrobial therapy.
Overall, 26 patients (14.8%) died because of leukemic
transformation (n = 3), cardiac diseases (n = 4), pneumonia/
sepsis (n = 8), acute respiratory distress syndrome (n = 1),
cholangiocellular cancer (n = 1), bleeding (n = 3), and
disease progression without leukemic transformation (n
= 6). Death occurred after a median ruxolitinib exposure
of 9.4 months (1–45.1 months); in no case the death was
directly attributed to therapy. Estimated OS at 1-year was
89.5% and the median follow up was 10 (1–55) months, as
shown in Figure 3. Estimated OS at 3-year from ruxolitinib
start was 72.3% in patients achieving a spleen response and
68.3% in patients without a spleen response. The mean OS
was 45.05 ± 2.8 months in patients who had reduction in
spleen size, whereas the mean OS was 38.24 ± 4.1 months
in patients who had no reduction in spleen size. Statistical
significance was not observed between OS and spleen
response (p = 0.73), as shown in Figure 4.

Table 2. Ruxolitinib treatment.
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Treatment details

Data

The median initial dose of ruxolitinib (mg)

30 (1–40)

Ruxolitinib dose modification (yes/no) (%) (n = 150)

69/81 (46/54)

The median duration of ruxolitinib (months)

12 (1–52)

Improvement of constitutional symptoms after ruxolitinib (yes/no) (%) (n = 152)

136 / 16 (89.4/10.6)

Improvement of spleen size after ruxolitinib treatment (yes/no) (%) (n = 150)

102/48 (68/32)

Spleen size after ruxolitinib treatment (mm)

199.49 ± 40.95

SOYER et al. / Turk J Med Sci

Figure 1. Mean percentage change from baseline to week 12 in ultrasonographic spleen
length.

Figure 2. Mean percentage change from baseline in palpable spleen length.
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Table 3. Logistic regression analysis between baseline factors, spleen, and constitutional symptom responses.
OR

95% CI

p-value

Age > 65 years

0.88

0.30–2.58

0.82

Sex (male)

1.14

0.46–2.81

0.76

Post-PV MF

1.63

0.84–3.15

0.14

DIPSS intermediate-1

0.70

0.22–2.22

0.55

Leukocytosis > 25.000/µL

1.21

0.30–4.89

0.78

Hemoglobin < 10 g/dL

2.44

0.84–7.07

0.09

Platelet < 200.000/µL

1.41

0.49–4.02

0.51

Blast cells > 1%

1.62

0.54–4.83

0.38

JAK2V617F mutation positive

1.02

0.36–2.91

0.95

Time between diagnosis to ruxolitinib treatment > 2 years

1.00

0.99–1.01

0.80

Age > 65 years

4.35

0.44–42.51

0.20

Sex male

0.88

0.19–3.95

0.86

Post-PV MF

0.11

0.11–1.91

0.06

DIPSS intermediate-1

2.16

1.30–35.7

0.32

Leukocytosis (> 25.000/µL)

0.52

0.06–4.21

0.54

Hemoglobin < 10 g/dL

1.39

0.28–6.75

0.68

Platelet < 200.000/µL

1.52

0.33–6.86

0.58

Blast cells > 1%

2.19

0.36–13.04

0.38

JAK2V617F mutation positive

0.16

0.01–1.68

0.08

Time between diagnosis to ruxolitinib treatment > 2 years

0.98

0.96–2.99

0.39

Spleen response

Constitutional symptoms response

4. Discussion
The aim of this retrospective and multicenter study was to
evaluate the efficacy and safety of ruxolitinib in Turkish
patients with MF in the real-life clinical practice. We
evaluated 176 patients from 15 centers across all of Turkey.
In our study, the median age at ruxolitinib treated
patients (62 years) was slightly lower than literature
(61.8–74 years) [11,13,14,18–24]. Sex and subtype of
myelofibrosis were similar to literature [11,13,18,20,22–
24]. Intermediate-2 risk patients (58.4%, n = 137) were
the most common prognostic group according to DIPSS
in this cohort, this finding was compatible with the
literature (30%–62.4%) [13,14]. In COMFORT-I and II
trials, patients were intermediate-II and high risk group
according to IPSS [6,7]. In our study, 32.1% of 137
patients who received ruxolitinib were intermediate-1
risk according to DIPSS and it was higher than literature
[13,14]. This higher rate may be associated with limited
effective treatment options for MF in the real life practice.
In the literature, rates of IPSS low and intermediate-I risk
group patients in real-life studies were between 11.8% and
31% [11,18,22]. One should not forget that most of our
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patients are from the compassionate use program, which
means that they were allowed in special conditions.
Most patients in this study experienced reduction
in spleen size (68%) and improvement in constitutional
symptoms (89.4%). These results were comparable with
previous study reported by Ellis et al. [14]. The rate of patients
achieving 50% or more reduction in palpable spleen size in
this study was similar to literature [11,14,18–20,22]. In this
study, both ultrasonographic and palpable spleen size were
evaluated. In the real-life setting, physical examination of
a patient is performed by various physicians in outpatient
clinics. Ultrasonography is a common, simple, and cheap
imaging technique. Although we did not evaluate spleen
volume with ultrasonography in all patients, spleen size
reduction after ruxolitinib treatment was significant in
both physical and ultrasonographic examination.
The median initial dose of ruxolitinib was 30 mg per
day in our analysis and this dose was compatible with
literature [14,18] but dose modification rate was lower
than reported in other studies (46% vs. 54%–88.9%)
[11,14,18,22,23]. Lower dose modification rate in our study
might be associated with lower initial dose rate than other

SOYER et al. / Turk J Med Sci
Table 4. Adverse events.
All grades, n = 132 (%)
Hematological adverse events
Anemia

32 (24.2)

Thrombocytopenia

25 (18.9)

Neutropenia

1 (0.75)

Nonhematologic adverse events
AST-ALT elevation

4 (3)

Fatigue

3 (2.3)

Urinary tract infection

3 (2.3)

Abdominal pain

2 (1.5)

Pneumonia

2 (1.5)

Zona zoster

2 (1.5)

Dizziness

1 (0.75)

Gingival bleeding

1 (0.75)

Rash

1 (0.75)

Palpitation

1 (0.75)

Electrolyte imbalance

1 (0.75)

Nausea

1 (0.75)

studies. In our study, 38.1% of patients started at the dose
of 20 mg BID, whereas 54.2%–63.6% of patients started at
the dose 20 mg BID in other studies [11,18,20,23]. After
dose modifications, the median dose of ruxolitinib was
still 30 mg per day in this study. There was no correlation
between maximum ruxolitinib doses achieved and spleen
response.
The most common hematological adverse events were
anemia (24.2%) and thrombocytopenia (18.9%) in our
study as expected. Anemia was relatively lower than other
studies (39.7%–62.7%) [11,18,22]. Thrombocytopenia
was slightly lower than others (25.5%–40.5%) [11,18,22].
The most common nonhematological adverse events were
abnormal hepatic (3%) function tests and infections (5.3%)
in this study. These rates were much lower compared to
other studies [11,18,22]. The lower rates of toxicities in our
study might be related to lower initial dose of ruxolitinib
and close monitorization of patients in terms of toxicities.
Since it is retrospective study, adverse event data might
have been reported less frequently.
Baseline factors were not associated with spleen
response and constitutional symptom response in our study.
In a retrospective study, high/intermediate-2 IPSS risk,
a large (≥ 10 cm below LCM) splenomegaly, transfusion
dependency, platelet count < 200 ´ 109/L, and a timeinterval between MF diagnosis and RUX start > 2 years

Figure 3. Overall survival after ruxolitinib treatment.
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Figure 4. Overall survival according to spleen size reduction after ruxolitinib treatment.

were significantly associated with lower spleen response
[20]. The same study was also evaluated pre-treatment
factors negatively correlating with symptom response. In
multivariate analysis, a baseline total symptom score (TTS)
> 20 had a significantly lower probability of achieving
a symptoms response at 6 months. In our study, because
numbers of intermediate-1 DIPSS risk patients were higher
than other studies, more patients who received ruxolitinib
had less advanced disease. The lack of correlation between
the spleen response and some baseline factors can be
explained with higher rate of less advanced disease and
relatively small patient population.
The estimated OS at 1 year was similar to JUMP trial
(89.5% vs. 94%) [11]. The estimated OS at 3 years from
ruxolitinib start was 72.3% in patients achieving a spleen
response and 68.3% in patients without a spleen response.
Although these rates were comparable with literature
(77.9% in patients achieving a spleen response and 68.4%
in patients without a spleen response, p = 0.034), statistical
significance was not shown in our study (p = 0.736) [20].
Lower initial dose of ruxolitinib in our study might be
associated with slightly lower spleen response.
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There are some limitations of this study. Firstly, this is
a retrospective study so, some of the data was not found
because of inadequate records. Secondly, a relatively small
patient population was included in our study compared
to the literature. Thirdly, spleen and constitutional
symptoms responses were evaluated with physicians’
reports. Ultrasonography was also used for imaging
the spleen response in many centers. But this technique
was not routinely used for evaluating spleen response in
studies.
In conclusion, ruxolitinib is a safe and effective
therapy in Turkish patients with MF. Indeed lower
initial ruxolitinib doses were associated with lower dose
modification rate; spleen response might be affected by
lower ruxolitinib doses. We can conclude that ruxolitinib
dose titration based on the current guidelines can provide
better responses in terms of not only clinical benefit but
also for long term of ruxolitinib treatment.
Informed consent
This study was approved by Ege University Ethical
Committee with a number of 16-6.1/9.
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